Knoll Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

Knoll Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-114,864	Closed	-$812K	–	13
2017 Q3	$812K	Sell	114,864 -57,350	-33%	-$432K	0.69%	12
2017 Q2	$1.35M	Hold	172,214	–	–	1.79%	8
2017 Q1	$1.37M	Hold	172,214	–	–	2.07%	8
2016 Q4	$2.53M	Buy	172,214 +12,883	+8%	+$193K	4.44%	6
2016 Q3	$2.8M	Hold	159,331	–	–	4.91%	7
2016 Q2	$5.01M	Hold	159,331	–	–	1.62%	4
2016 Q1	$4.23M	Hold	159,331	–	–	1.72%	5
2015 Q4	$7M	Hold	159,331	–	–	2.6%	4
2015 Q3	$6.74M	Hold	159,331	–	–	2.86%	4
2015 Q2	$7.29M	Hold	159,331	–	–	2.35%	4
2015 Q1	$6.28M	Buy	159,331 +35,715	+29%	+$1.57M	1.83%	4
2014 Q4	$3.23M	Buy	123,616 +25,473	+26%	+$810K	1.27%	4
2014 Q3	$10.6M	Hold	98,143	–	–	4.13%	3
2014 Q2	$11.9M	Hold	98,143	–	–	5.3%	3
2014 Q1	$12.5M	Hold	98,143	–	–	6.45%	3
2013 Q4	$12.4M	Buy	98,143 +14,286	+17%	+$1.8M	6.23%	3
2013 Q3	$10.6M	Hold	83,857	–	–	5.65%	3
2013 Q2	$4.02M	Buy	+83,857	New	+$4.11M	2.75%	3

Other funds holding ARCT

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Knoll Capital Management's ARCT Position: Q4 2017 in Review

Knoll Capital Management sold out of Arcturus Therapeutics (ARCT) in Q4 2017, closing a stake of 114,864 shares — an estimated $812K sold.

Knoll Capital Management first reported a position in ARCT in Q2 2013 and held it in 18 quarters. The position peaked at $12.5M in Q1 2014. 19 funds tracked by Wall St. Rank hold ARCT as of Q4 2017.

Knoll Capital Management reported no remaining Arcturus Therapeutics position as of Q4 2017 after selling out during the quarter.
Knoll Capital Management sold 114,864 Arcturus Therapeutics shares in Q4 2017, an estimated $812K.
Knoll Capital Management first reported a position in Arcturus Therapeutics in Q2 2013 and held it in 18 quarters.
Knoll Capital Management's Arcturus Therapeutics position peaked at $12.5M in Q1 2014.
19 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2017.

Based on Knoll Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.